Cashu
Precigen Develops PAPZIMEOS™ for Treating Respiratory Papillomatosis and Advances in Immunology
1 day ago
Stocks
Health Care
pgen
Precigen
NASDAQ: PGEN
+0.01 (+0.25%)
3.94
USD
At close at Apr 03, 18:07 UTC
Overview
Loading chart...
Key Stats
Market Cap
1.39B
Dividend Yield
0.00%
P/E Ratio
-3.24
EPS
-0.48
Revenue
3.92M
Avg. Volume
8.79M
About
What does PGEN do?
Precigen, a biotechnology company headquartered in Germantown, Maryland, focuses on synthetic biology technologies and develops therapies for urgent diseases. Founded in 2013, it operates through Biopharmaceuticals and Exemplar segments.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.